CONSULTING SERVICES AGREEMENTConsulting Services Agreement • August 5th, 2011 • Emergent BioSolutions Inc. • Pharmaceutical preparations • Delaware
This Consulting Services Agreement (“Agreement”), effective the 1st day of April 2011 (the “Effective Date”), is made and entered into by and between Emergent BioSolutions Inc. (“Emergent”), a Delaware corporation, with offices at 2273 Research Boulevard, Suite 400, Rockville, Maryland 20850, and The Hauer Group (“Consultant”), located at 7850 Southdown Road, Alexandria, VA 22308, Emergent and Consultant are sometimes hereinafter referred to in the singular as “Party” and collectively as the “Parties”.
AMENDED AND RESTATED LICENSE AND COMMERCIALIZATION AGREEMENT between GENMAB A/S and TENX BIOPHARMA, INC. Dated as of December 22, 2009License and Commercialization Agreement • August 5th, 2011 • Emergent BioSolutions Inc. • Pharmaceutical preparations • New York
Dated 17 May 2011 Agreement for surrender of premises known as 530/535 and 545 IQ Winnersh Wokingham Berkshire Eversheds LLP Cardiff CF10 5BT Tel 0845 497 9797 Fax 0845 498 7333 Int +44 29 2047 1147Emergent BioSolutions Inc. • August 5th, 2011 • Pharmaceutical preparations • Slough
Clause Page 1 INTERPRETATION 1 1.1 Defined terms 1 1.2 Construction 3 1.3 Contracts (Rights of Third Parties) Act 1999 3 1.4 Particulars 3 1.5 Commercial Conditions 3 2 AGREEMENT TO SURRENDER 3 2.1 Agreement 3 2.2 Consideration 4 2.3 Completion 6 2.4 Timing for completion 6 2.5 Possession 6 2.6 Condition 6 2.7 Landlord’s Inspection of the Works 8 2.8 Authorisation of Agreement 8 3 TITLE 8 3.1 Title deduced 8 3.2 Title guarantee 9 4 PENDING COMPLETION 9 4.1 Terms of the Lease 9 4.2 Tenant’s obligations 9 5 COMPLETION 9 5.1 Handover of the Premises 9 5.2 Release of obligations 10 5.3 Rent arrears 10 5.4 Reimbursement of rent 10 5.5 Service charge 11 6 ADDITIONAL PROVISIONS 11 6.1 Information provided 11 6.2 Entire agreement 11 6.3 VAT 11 6.4 Deed of Variation 11 6.5 Non-Merger 12 6.6 Splitting of Electricity Supply to 540 and 545 Eskdale Road 12 7 SIGNING 12 Schedules 1 Variations to the Commercial Conditions 30 Appendices 1 Deed of Variation 30 2 Deeds of Surrender 30 3 List of Plant an
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. WYETH LLC ACTING THROUGH ITS WYETH PHARMACEUTICALS DIVISION Collegeville, Pennsylvania 19426 USAEmergent BioSolutions Inc. • August 5th, 2011 • Pharmaceutical preparations
This letter agreement (the “Letter Agreement”) constitutes Amendment No. 3 to the Agreement referred to above. Capitalized terms used but not defined herein shall have the meanings set forth in the Agreement. EPDS and Wyeth desire to amend the Agreement with respect to the restrictions on Development and Commercialization of CD20 Antigens and CD20 Products. This Letter Agreement sets forth the agreement of EPDS and Wyeth with respect to such amendment.
Dated 17 May 2011Emergent BioSolutions Inc. • August 5th, 2011 • Pharmaceutical preparations
relating to a lease dated 13 December 1996 made between (1) Slough Properties Limited and (2) Azur Environmental Limited in respect of 540 IQ Winnersh Wokingham Berkshire
